N⁴-(2-bromo-4-isopropylphenyl)-N⁶-butyl-N⁶-ethyl-5-(ethylthio)-2-methylpyrimidine-4,6-diamine | 1606178-46-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N⁴-(2-bromo-4-isopropylphenyl)-N⁶-butyl-N⁶-ethyl-5-(ethylthio)-2-methylpyrimidine-4,6-diamine
• 英文别名: 6-N-(2-bromo-4-propan-2-ylphenyl)-4-N-butyl-4-N-ethyl-5-ethylsulfanyl-2-methylpyrimidine-4,6-diamine
• CAS: 1606178-46-4
• 化学式: C₂₂H₃₃BrN₄S
• 分子量: 465.501
• InChiKey: PRQZXNYKCHDCRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  66.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-((2-bromo-4-isopropylphenyl)amino)-5-(ethylthio)-2-methylpyrimidin-4(3H)-one 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 、 三氯氧磷 作用下， 生成 N⁴-(2-bromo-4-isopropylphenyl)-N⁶-butyl-N⁶-ethyl-5-(ethylthio)-2-methylpyrimidine-4,6-diamine
  参考文献：
  名称：

  Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands

  摘要：

  Corticotropin releasing factor (CRF) is a neuropeptide hormone produced from the hypothalamus that controls the secretion of corticotropin (ACTH) from the anterior pituitary gland that, in turn, prompts the adrenal glands to secrete glucocorticoids. This involvement in the hypothalamic-pituitary-adrenal axis (HPA) in response to stress and also playing a key role in behavioral, cardiovascular, immune and gastrointestinal systems made CRF binding to its receptors an important target in drug discovery aiming to develop lead compounds with the potential to treat various stress-related disorders including depression, anxiety and addictive disorders. Several non-peptide CRF1 receptor antagonists were developed by pharmaceutical companies and are currently in clinical trials with the aim of improving the health consequences of chronic stress and for use in the clinical management of anxiety and stress. Many showed promising results not only in treatment of anxiety and depression but also in treatment of CRF-induced hypertension, as well as in treatment of arthritis, irritable bowel syndrome and peptic ulcers. In this manuscript, we describe the synthesis of substituted pyrimidines with close structural similarities to reported lead compounds with promising CRF1 receptor affinities and carrying groups known to be associated with optimum affinity to CRF1 receptors. The affinity of the newly prepared compounds in comparison to antalarmin, a potent CRF1 receptor antagonist in clinical trials as a standard, is also described. Four compounds from the new series showed promising CRF1 receptor affinity. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.040

文献信息

• Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands
  作者：Bhimanna Kuppast、Katerina Spyridaki、George Liapakis、Hesham Fahmy

  DOI：10.1016/j.ejmech.2014.03.040

  日期：2014.5

  Corticotropin releasing factor (CRF) is a neuropeptide hormone produced from the hypothalamus that controls the secretion of corticotropin (ACTH) from the anterior pituitary gland that, in turn, prompts the adrenal glands to secrete glucocorticoids. This involvement in the hypothalamic-pituitary-adrenal axis (HPA) in response to stress and also playing a key role in behavioral, cardiovascular, immune and gastrointestinal systems made CRF binding to its receptors an important target in drug discovery aiming to develop lead compounds with the potential to treat various stress-related disorders including depression, anxiety and addictive disorders. Several non-peptide CRF1 receptor antagonists were developed by pharmaceutical companies and are currently in clinical trials with the aim of improving the health consequences of chronic stress and for use in the clinical management of anxiety and stress. Many showed promising results not only in treatment of anxiety and depression but also in treatment of CRF-induced hypertension, as well as in treatment of arthritis, irritable bowel syndrome and peptic ulcers. In this manuscript, we describe the synthesis of substituted pyrimidines with close structural similarities to reported lead compounds with promising CRF1 receptor affinities and carrying groups known to be associated with optimum affinity to CRF1 receptors. The affinity of the newly prepared compounds in comparison to antalarmin, a potent CRF1 receptor antagonist in clinical trials as a standard, is also described. Four compounds from the new series showed promising CRF1 receptor affinity. (C) 2014 Elsevier Masson SAS. All rights reserved.